IL17A and B-cell chronic lymphocytic leukemia: Other researchers have asserted that Th17/IL-17 has protective action and that B-CLL patients with advanced-stage disease have minor concentrations of Th17/IL-17 [168], and Th-17 and IL-17A levels were reduced in patients with adverse prognostic factors.